Intratio
Loading...
Skip to main content
Model output · Signal date Oct. 14, 2026

Daily Signals

2489 companies scored · 2026-10-14 run in progress: 1697 of ~5379 signals so far · Total · absolute moveSwitch to Alpha · 30D 90D

Signal date 2026-10-14 Cut-offs from the 2026-10-13 run
Companies scored 2489 IC ≥ 0 · market cap ≥ $100M
Median forecast +1.01% Total · 30D
Long–short spread +2.21% Strong Buy minus Strong Sell, mean
Median IC 0.29 Spearman · 30D
Rating changes ▲ 92 ▼ 76 vs the previous run
Cross-section

Distribution of the day's forecasts

30D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

288 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
51 PTCTPTC THERAPEUTICS, INC. Life Sciences 0.25 $5.0B Neutral +1.07% +2.62% ·
52 TVTXTravere Therapeutics, Inc. Life Sciences 0.32 $4.9B Unlock rating and forecasts
53 COGTCogent Biosciences, Inc. Life Sciences 0.32 $4.9B Unlock rating and forecasts
54 AMRNAMARIN CORP PLC\UK Life Sciences 0.14 $4.9B Neutral +1.09% +2.46% ·
55 CRSPCRISPR Therapeutics AG Life Sciences 0.12 $4.8B Unlock rating and forecasts
56 GPCRStructure Therapeutics Inc. Life Sciences 0.06 $4.8B Unlock rating and forecasts
57 DFTXDefinium Therapeutics, Inc. Life Sciences 0.29 $4.6B Unlock rating and forecasts
58 DNTHDianthus Therapeutics, Inc. /DE/ Life Sciences 0.48 $4.3B Unlock rating and forecasts
59 INDVIndivior Pharmaceuticals, Inc. Life Sciences 0.35 $4.2B Neutral +0.73% +2.97% ▲ 1
60 TNGXTango Therapeutics, Inc. Life Sciences 0.35 $4.1B Unlock rating and forecasts
61 ADPTAdaptive Biotechnologies Corp Life Sciences 0.08 $4.0B Unlock rating and forecasts
62 EWTXEdgewise Therapeutics, Inc. Life Sciences 0.23 $3.9B Unlock rating and forecasts
63 ABCLAbCellera Biologics Inc. Life Sciences 0.51 $3.9B Unlock rating and forecasts
64 RLAYRelay Therapeutics, Inc. Life Sciences 0.45 $3.8B Unlock rating and forecasts
65 TLXTelix Pharmaceuticals Ltd Life Sciences 0.06 $3.7B Unlock rating and forecasts
66 OGNOrganon & Co. Life Sciences 0.50 $3.6B Unlock rating and forecasts
67 XENEXenon Pharmaceuticals Inc. Life Sciences 0.44 $3.5B Unlock rating and forecasts
68 VKTXViking Therapeutics, Inc. Life Sciences 0.03 $3.3B Unlock rating and forecasts
69 IDYAIDEAYA Biosciences, Inc. Life Sciences 0.17 $3.3B Unlock rating and forecasts
70 ARQTArcutis Biotherapeutics, Inc. Life Sciences 0.17 $3.3B Unlock rating and forecasts
71 TARSTarsus Pharmaceuticals, Inc. Life Sciences 0.05 $3.3B Neutral +1.06% +3.69% ·
72 ACADACADIA PHARMACEUTICALS INC Life Sciences 0.51 $3.2B Unlock rating and forecasts
73 AMLXAmylyx Pharmaceuticals, Inc. Life Sciences 0.21 $3.0B Unlock rating and forecasts
74 DNLIDenali Therapeutics Inc. Life Sciences 0.16 $2.9B Unlock rating and forecasts
75 ELVNEnliven Therapeutics, Inc. Life Sciences 0.40 $2.9B Unlock rating and forecasts
76 RCUSArcus Biosciences, Inc. Life Sciences 0.32 $2.9B Unlock rating and forecasts
77 DYNDyne Therapeutics, Inc. Life Sciences 0.14 $2.9B Unlock rating and forecasts
78 PGENPRECIGEN, INC. Life Sciences 0.43 $2.7B Unlock rating and forecasts
79 DBVTDBV Technologies S.A. Life Sciences 0.18 $2.7B Neutral +1.10% +1.52% ·
80 RADXRadiopharm Theranostics Ltd Life Sciences 0.21 $2.6B Neutral +0.73% +0.68% ▲ 1
81 NEOGNEOGEN CORP Life Sciences 0.30 $2.6B Unlock rating and forecasts
82 BEAMBeam Therapeutics Inc. Life Sciences 0.26 $2.5B Unlock rating and forecasts
83 LQDALiquidia Corp Life Sciences 0.23 $2.4B Unlock rating and forecasts
84 ADMAADMA BIOLOGICS, INC. Life Sciences 0.51 $2.3B Neutral +1.11% +3.51% ·
85 PBHPrestige Consumer Healthcare Inc. Life Sciences 0.36 $2.3B Neutral +0.80% +0.45% ·
86 NRIXNurix Therapeutics, Inc. Life Sciences 0.23 $2.3B Neutral +0.96% +2.65% ·
87 CLDXCelldex Therapeutics, Inc. Life Sciences 0.24 $2.2B Unlock rating and forecasts
88 BHCBausch Health Companies Inc. Life Sciences 0.37 $2.2B Unlock rating and forecasts
89 AUPHAurinia Pharmaceuticals Inc. Life Sciences 0.16 $2.2B Unlock rating and forecasts
90 HRMYHarmony Biosciences Holdings, Inc. Life Sciences 0.31 $2.2B Neutral +0.99% +3.11% ·
91 PRGOPERRIGO Co plc Life Sciences 0.56 $2.1B Unlock rating and forecasts
92 NVAXNOVAVAX INC Life Sciences 0.32 $2.1B Unlock rating and forecasts
93 VCELVericel Corp Life Sciences 0.27 $2.1B Neutral +0.76% +3.02% ·
94 VRDNViridian Therapeutics, Inc.\DE Life Sciences 0.51 $2.1B Unlock rating and forecasts
95 BCRXBIOCRYST PHARMACEUTICALS INC Life Sciences 0.59 $2.1B Neutral +1.05% +3.59% ·
96 TRLVTrulieve Cannabis Corp. Life Sciences 0.06 $2.0B Unlock rating and forecasts
97 VERAVera Therapeutics, Inc. Life Sciences 0.09 $2.0B Unlock rating and forecasts
98 IMNMImmunome Inc. Life Sciences 0.11 $2.0B Unlock rating and forecasts
99 SDGRSchrodinger, Inc. Life Sciences 0.46 $1.9B Unlock rating and forecasts
100 LKFTLakefront Biotherapeutics NV Life Sciences 0.33 $1.9B Neutral +0.73% +1.95% ▲ 1
51–100 of 288 Previous Next
Since the previous run

Rating changes

▲ 92▼ 76
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-13) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected absolute price move over the horizon, market included. This is the number a price target is built from. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.